Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases.

Hiroyasu KanedaKenji SawaHaruko DagaAsuka OkadaYuki NakataniShinji AtagiKyoichi OkishioYoko TaniYoshiya MatsumotoKoichi OgawaKenji NakahamaMotohiro IzumiShigeki MitsuokaTomoya Kawaguchi

Published in: Investigational new drugs (2021)

Ramucirumab in combination with erlotinib or osimertinib showed safety for EGFR-mutated NSCLC with brain metastases.

Keyphrases

brain metastases
small cell lung cancer
epidermal growth factor receptor
advanced non small cell lung cancer
tyrosine kinase
wild type